hotspot -WSS

hotspot

author：entertainment 2025-10-02 06:40:16 - browse：9168

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Why Novartis is changing the name of its research labs

WSS

What American doctors can learn from their Israeli counterparts

Bernie Sanders bashes nonprofit hospitals over their tax breaks

ALS advocates say criticism of new drugs misses bigger picture

Stem cell treatment guidelines are released by FDA

Peter Marks talks Operation Warp Speed for Rare Diseases

A revolution in caring for preterm infants

focus

hotspot

focus

Drug repurposing or repositioning? The language matters

A fraught question for the kids of Alzheimer’s: Is it coming for us?

At least 13 dead in Texas as scorching temps continue

What drug price negotiations mean for Medicare Part D

Drug repurposing or repositioning? The language matters

How to fix cancer clinical trials' diversity problem

Tori Bowie and the unacceptable rates of Black maternal death

House transparency, PBM reform bill gains bipartisan support

Malaria cases in Florida and Texas: Here’s what you need to know

Medicaid rebukes states for mistakenly disenrolling children

Wikipedia

AstraZeneca chief proposes a novel edit to the drug pricing bill

Akero's treatment for NASH falls short in cirrhosis study

AstraZeneca chief proposes a novel edit to the drug pricing bill

Life sciences deals on track to hit lowest point since 2017

NIH nominee Bertagnolli will get October confirmation hearing

Akero's treatment for NASH falls short in cirrhosis study

hotspot

hotspot

Wikipedia

focus